Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Jul 13;19(1):177.
doi: 10.1186/s12882-018-0956-8.

Preservation of kidney function in kidney transplant recipients by alkali therapy (Preserve-Transplant Study): rationale and study protocol

Anna Wiegand  1 , Alexander Ritter  1 , Nicole Graf  2 , Spyridon Arampatzis  3 , Daniel Sidler  3 , Karine Hadaya  4 , Thomas F Müller  1 , Carsten A Wagner  5 , Rudolf P Wüthrich  1 , Nilufar Mohebbi  6
Affiliations
Clinical Trial

Preservation of kidney function in kidney transplant recipients by alkali therapy (Preserve-Transplant Study): rationale and study protocol

Anna Wiegand et al. BMC Nephrol. .

Abstract

Background: Graft survival after kidney transplantation has significantly improved within the last decades but there is a substantial number of patients with declining transplant function and graft loss. Over the past years several studies have shown that metabolic acidosis plays an important role in the progression of Chronic Kidney Disease (CKD) and that alkalinizing therapies significantly delayed progression of CKD. Importantly, metabolic acidosis is highly prevalent in renal transplant patients and a recent retrospective study has shown that metabolic acidosis is associated with increased risk of graft loss and patient death in kidney transplant recipients. However, no prospective trial has been initiated yet to test the role of alkali treatment on renal allograft function.

Methods: The Preserve-Transplant Study is an investigator-initiated, prospective, patient-blinded, multi-center, randomized, controlled phase-IV trial with two parallel-groups comparing sodium bicarbonate to placebo. The primary objective is to test if alkali treatment will preserve kidney graft function and diminish the progression of CKD in renal transplant patients by assesing the change in eGFR over 2 years from baseline. Additionally we want to investigate the underlying pathomechanisms of nephrotoxicity of metabolic acidosis.

Discussion: This study has the potential to provide evidence that alkali treatment may slow or reduce the progression towards graft failure and significantly decrease the rate of end stage renal disease (ESRD), thus prolonging long-term graft survival. The implementation of alkali therapy into the drug regimen of kidney transplant recipients would have a favorable risk-benefit ratio since alkali supplements are routinely used in CKD patients and represent a well-tolerated, safe and cost-effective treatment.

Trial registration: ClinicalTrials.gov NCT03102996 . Trial registration was completed on April 6, 2017.

Keywords: Graft function; Graft outcome; Metabolic acidosis; Sodium bicarbonate; eGFR.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study was approved by the lead cantonal ethics committee in Zurich (Switzerland) and the cantonal ethics committee in Berne (Switzerland) and Geneva (Switzerland), Registration number: 2016–02012.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Study Flowchart of the Preserve-Transplant Study. Numbers in circles define each study visit. Study visits 2, 7, and 11 include in addition to blood and spot urine tests 24 h-ambulatory blood pressure monitoring and 24 h urine collection
See this image and copyright information in PMC

References

    1. Santos J, Martins LS. Estimating glomerular filtration rate in kidney transplantation: still searching for the best marker. World J Nephrol. 2015;4(3):345–353. doi: 10.5527/wjn.v4.i3.345. - DOI - PMC - PubMed
    1. U.S. Department of Health & Human Services. Am J Transplant. 2014;14(Suppl 1):11-44. 10.1111/ajt.12579, http://srtr.transplant.hrsa.gov/annualreports/2012/pdf/01kidney_13.pdf.
    1. Collaborative Transplant Study [www.ctstransplant.org].
    1. Kopple JD, Kalantar-Zadeh K, Mehrotra R. Risks of chronic metabolic acidosis in patients with chronic kidney disease. Kidney Int Suppl. 2005;(95):S21–7. - PubMed
    1. Kraut JA, Madias NE. Metabolic acidosis of CKD: an update. Am J Kidney Dis. 2016;67(2):307–317. doi: 10.1053/j.ajkd.2015.08.028. - DOI - PubMed

Publication types

Associated data